Overview

Phase III, Long-term, Open-label Safety Study of Z-338

Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long-term safety of 100 mg Z-338 TID in European subjects with FD.
Phase:
Phase 3
Details
Lead Sponsor:
Zeria Pharmaceutical
Treatments:
Z 338